Correction to Lancet Oncol Correction to Lancet Oncol Correction to Lancet Oncol 2015; 16: e227 2015; 16: 738 2015; 16: 747 Lowy DR, Herrero R, Hildesheim A, for the Participants in the IARC/NCI workshop on Primary Endpoints for Prophylactic HPV Vaccine Trial. Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. Lancet Oncol 2015; 16: e226–33— In the panel, in the section on the quadrivalent vaccine for men, the second bullet point should read: “Approved in the EU by the EMA for the prevention of vaccine-type related anal lesions and for the prevention of vaccine-type related genital warts (ages ≥9). For ages 9–13, a two dose vaccine schedule is approved*; for ages 14 years or older a three-dose vaccine schedule is approved.” This correction has been made to the online version as of June 29, 2015.
Schiller JH. Anti-EGFR monoclonal antibodies in lung cancer treatment. Lancet Oncol 2015; 16: 738–39—In this Comment, the chemotherapy backbone used in the SQUIRE trial was incorrectly referred to as “gemcitabine and carboplatin” in four instances in the third paragraph; it should read “gemcitabine and cisplatin”. These corrections have been made to the online version as of June 29, 2015, and the printed version is correct.
Torri V, Broggini M, Garassino MC. EGFR mutations and EGFR tyrosine kinase inhibitors. Lancet Oncol 2015; 16: 746–48—The seventh sentence of the ﬁnal paragraph of this Comment should read: “Results for Leu858Arg are still inconclusive because although progression-free survival is higher in patients given all EGFR inhibitors versus chemotherapy, overall survival seems to be better with chemotherapy than with afatinib for these patients.” This correction has been made to the online version as of June 29, 2015, and the printed version is correct.
Correction to Lancet Oncol 2015; 16: e316 Bagcchi S. New scale assesses beneﬁts of cancer medicines. Lancet Oncol 2015; 16: e316—In this News item, the ﬁnal two sentences of paragraph 3 should have read: “According to the scale, treatment of late-stage EGFR-mutated nonsquamous lung cancer with erlotinib provides a gain in progression-free survival (PFS) of 8·5 months (hazard ratio [HR] 0·16 [95% CI 0·10–0·26]) and an improvement in quality of life compared with carboplatin and gemcitabine, earning an ESMO-MCBS score of 4/5. In contrast, the same drug when used to treat metastatic pancreatic cancer provides an overall gain of only 9 days compared with chemotherapy treatment, and had a score of 1/5.” This correction has been made as of June 12, 2015.
www.thelancet.com/oncology Vol 16 July 2015
Published Online June 12, 2015 http://dx.doi.org/10.1016/ S1470-2045(15)00056-X